Share Twitter LinkedIn Facebook Email Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on the long-term Checkmate-004 in metastatic melanoma and provides outcomes from the study. Advertisement
TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Melanoma Skin Cancer Treatment 1 Min Read
63% pCR Rate with Neoadjuvant Nivolumab + Relatlimab in Resectable Melanoma Melanoma Skin Cancer Treatment 4 Mins Read